EXCLUSIVE: Sophia Anne Caruso (Beetlejuice, The School for Good and Evil), Mark Penwill (Catch Me a Killer) and Anton David Jeftha (Legacy) have joined the Season 2 cast of Netflix‘s One Piece ...

EXCLUSIVE: Sophia Anne Caruso (Beetlejuice, The School for Good and Evil), Mark Penwill (Catch Me a Killer) and Anton David Jeftha (Legacy) have joined the Season 2 cast of Netflix’s One Piece ...

The Scorpion King collection is a spin-off to The Mummy Returns and follows the story of Mathayus and his rise to become the Scorpion King. The franchise began with the 2002 film The Scorpion King ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

Investing.com -- Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including ...

Eli Lilly will acquire Scorpion's PI3Kα inhibitor STX-478 for up to $2.5 billion, including a $1 billion upfront payment. Scorpion will spin out a new entity, retaining non-PI3Kα assets ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...